Stage IV Bladder Cancer AJCC v8 Recruiting Phase 2 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0109735 (Stage IV Bladder Cancer AJCC v8)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03601455Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder CancerTreatment